How are energy investors positioned?
Ashiya Mona, a director at Disc Medicine, Inc. (NASDAQ:IRON), has recently sold a significant portion of her holdings in the company. According to a recent SEC filing, Mona disposed of shares totaling approximately $2.83 million. The transactions were executed over three consecutive days from March 19 to March 21, 2025, with sale prices ranging between $54.00 and $54.02 per share. The stock, currently trading at $52.24, sits well above its 52-week low of $25.60 but below its high of $68.73. According to InvestingPro analysis, the company appears overvalued at current levels.
The filings indicate multiple sales of Disc Medicine’s common stock. On March 19, Mona sold a total of 39,656 shares, followed by the sale of 2,762 shares on March 20, and concluding with 10,011 shares on March 21. These transactions were conducted indirectly, with the ownership nature linked to OrbiMed Private Investments and OrbiMed Genesis Master Fund, as detailed in the footnotes of the filing. The stock has shown significant volatility with a beta of 2.85, making it nearly three times more volatile than the broader market.
Post-transaction, Mona’s holdings in Disc Medicine remain substantial, with nearly 1.42 million shares still under her indirect ownership. The sales are part of routine portfolio management and do not necessarily indicate any change in Mona’s confidence in the company. With a market capitalization of $1.82 billion and analyst price targets ranging from $75 to $132, InvestingPro subscribers can access 8 additional key insights about IRON’s financial health and future prospects through the comprehensive Pro Research Report.
In other recent news, Disc Medicine has been the focus of several analyst updates and strategic developments. Cantor Fitzgerald has maintained its Overweight rating on Disc Medicine, keeping the price target steady at $99. This decision follows updates in the company’s financial model, reflecting a recent public offering that increased the number of shares and revised operating expense projections. Scotiabank (TSX:BNS) raised its price target for Disc Medicine to $75 from $73, maintaining a Sector Outperform rating. This adjustment comes as the company aims for a New Drug Application submission for bitopertin by the second half of 2025, with potential market entry in 2026.
TD Cowen initiated coverage on Disc Medicine with a Buy rating, expressing optimism about the market potential of bitopertin and another treatment, 0974, in the myelofibrosis anemia space. Stifel also increased its price target for the company to $94, maintaining a Buy rating, following Disc Medicine’s authorization to submit an NDA for bitopertin. The analyst at Stifel estimates an 85% chance of approval for bitopertin, with a commercial launch expected in 2026. These developments indicate a strong focus on expanding Disc Medicine’s market presence and advancing its drug pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.